Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: A mediation effect analysis

Ling-Chun Lu | Shiow-Luan Tsay | Sou-Yi Chang | Chung-Ming Chen | Chieh-Yu Liu

Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) with restriction of daily activity (RDA) was a common consequence of oxaliplatin-based chemotherapy in colorectal cancer patients. CIPN with RDA and negative mood may impact the quality of life (QoL). However, the relationships among RDA, mood, and QoL remain unclear. This was a cross-sectional relative study in which four instruments were used: the Neuropathic Pain Symptom Inventory was used to measure the severity of CIPN; the Screening of Activity Limitation and Safety Awareness scale was used to evaluate RDA; the Profile of Mood States Short Form was used to assess negative mood; and the Functional Assessment Cancer Center Therapy-Colorectal scale version 4 was used to evaluate QoL. Relationships among the variables were analyzed by bivariate correlation, hierarchical multiple linear regression, and Baron and Kenny's mediation testing. One hundred three colorectal adenocarcinoma patients with CIPN after receiving oxaliplatin-based chemotherapy were enrolled. Patients had mild-to-moderate CIPN and mild RDA. Significant correlations were found between CIPN and mood ($r = 0.425$, $P < 0.001$), between RDA and mood ($r = 0.343$, $P < 0.001$), and between RDA and QoL ($r = 0.285$, $P < 0.01$). RDA and mood may impact QoL. Under mediation effect analysis, mood mediated 38.48% of the effect of RDA on QoL ($P < 0.001$). Negative mood is the major factor impacting QoL in colorectal cancer patients with CIPN. Although the management of CIPN and RDA can prevent irreversible functional problems, enhancing the adaption of mood disturbance can strongly promote their QoL.

KEYWORDS
chemotherapy-induced peripheral neuropathy, daily activity, mediation effect analysis, mood, quality of life

1 | INTRODUCTION
Colorectal cancer is the third most common cancer in terms of incidence and the fourth most common cancer in terms of mortality worldwide. Oxaliplatin-based chemotherapy is beneficial in the treatment of colorectal cancer in adjuvant, advanced and metastatic settings. After patients receive the therapy, approximately 72%-95.2% of them consequently
experience acute or chronic peripheral neuropathy.3,4 These acute peripheral neuropathic symptoms may develop after the first course of treatment but may be relieved spontaneously between courses.4,5 When the total accumulative dose of oxaliplatin is approximately 540-850 mg/m², the symptoms may last for months or years.3,5,6 Acute peripheral neuropathic symptoms in the limbs include paresthesia, dysesthesia, neuropathic pain, painful muscle spasm, and evoked hypersensitivity as touching cold objects. Chronic peripheral neuropathic symptoms in the limbs comprise persistent paresthesia, dysesthesia, altered proprioception, sensory ataxia, progressive sensory loss, and decreased vibratory and temperature sensation.3-7 When patients had chemotherapy-induced peripheral neuropathy (CIPN) in the limbs, the condition often concurred with restriction of daily activity (RDA).5,8,9

When CIPN occurs in the upper limbs, patients may have interference with dressing, household chores, hobbies, and work.9 As they wear clothing, they may have problems with buttoning, using zippers, fastening brassieres, tying neckties, and putting on earrings or jewelry.5,10 They may have difficulty in opening jars, removing cold objects from the refrigerator, threading a needle, using remote controls or controllers for video games or picking up small objects from the ground.10,11 When CIPN develops in the feet, the patient’s walking, climbing stairs, hiking, running, biking, exercise, or standing for a long time may be interfered.10 The evoked hypersensitivity as touching cold objects causes patients to not go barefoot, and the paresthesia, dysesthesia, neuropathic pain, painful muscle spasm, and leg weakness lead to imbalance.9-11 Thus, the risk of falls increases in colorectal cancer patients with CIPN.12

The impact of CIPN on mood or quality of life (QoL) has been clearly demonstrated in several studies.11,13,14 Patients with CIPN often also show RDA; however, the relationship among RDA, mood, and QoL remains unclear in colorectal cancer patients with CIPN.8,10,13-16 When patients with CIPN also show functional limitations, such as slipping, falling or abnormal walking, they often express annoyance, irritability, weariness, frustration, anger, and depression.10 Patients with CIPN and functional limitation show poorer emotional status and QoL.8,13,14 When patients with CIPN develop social limitation, such as withdrawal from hobbies, leisure, work or family roles, they experience emotional distress.10,11 Cancer patients with anxiety, depression, and hopelessness may show effects on QoL.15 In addition, cancer patients with depression and anxiety showed significantly poorer QoL.16,17

The relationships among RDA, mood, and QoL in colorectal cancer patients with CIPN seem to be complex. The aim of this study was to investigate the relationships among RDA, mood, and QoL in colorectal cancer patients with CIPN.

## METHODS

### Participants and procedure

This is a cross-sectional relative study. Patients who were hospitalized at two cancer centers in Taiwan in 2011 were recruited. The inclusion criteria were as follows: (a) diagnosis of adenocarcinoma by surgical pathology and the cancer located in the colon or rectum; (b) received oxaliplatin-based chemotherapy; (c) new peripheral neuropathic symptoms in the extremities after receiving oxaliplatin-based chemotherapy; and (d) ability to understand and answer the questionnaires as well as ability to obey requirements to assess RDA. In the study, the symptoms of CIPN in the limbs included paresthesia, dysesthesia, neuropathic pain, painful muscle spasm or weakness, and hypersensitivity to cold objects. This study was approved by the Institutional Review Boards of Koo Foundation, Sun Yat-Sen Cancer Center and Taipei Tzu Chi Hospital (Approval No: 00-IRB-005-M). Signed informed consent was obtained from all participants before data collection. Four of the one hundred seven recruited patients refused the invitation because of poor concentration and fatigue related to chemotherapy.

### Instruments

Four instruments were included in the study: (a) the Neuropathic Pain Symptoms Inventory (NPSI) was used to measure the severity of various CIPN symptoms, (b) the Screening of Activity Limitation and Safety Awareness (SALSA) scale was used to evaluate RDA, (c) the Profile of Mood States Short Form (POMS-SF) was used to assess negative mood, and (d) the Functional Assessment Cancer Center Therapy-Colorectal scale (FACT-C) version 4 was used to evaluate QoL.

### Neuropathic Pain Symptoms Inventory

NPSI was established by Bouhassira and colleagues in 2004.18 The inventory consists of 12 items and four subscales. The four subscales are spontaneous pain, paroxysmal pain, evoked pain, and dysesthesia/paresthesia. Ten of the items are quantified on a 0-10 numerical scale to evaluate the severity of diverse neuropathic pain symptoms during the past 24 hours. The other two items have 5-point Likert-type questions to evaluate the duration of spontaneous pain and frequency of paroxysmal pain, respectively. Higher scores on the total scale indicate more severity of neuropathy. Its reliability was high (Cronbach’s α coefficient of the total scale was 0.90), and the construct validity by factor analysis was significant ($P < 0.001$).18
scale also demonstrated adequate reliability and content validity for evaluating patients with peripheral neuropathic pain in the United States, Brazil, Japan, China, Finland, and Spain. The reliability of the Chinese version of the NPSI for evaluating oxaliplatin-induced peripheral neuropathy was high (Cronbach's $\alpha$ coefficient of the total scale was 0.90), the construct validity by confirmatory factor analysis with goodness-of-fit indices, included normed chi-square ($\chi^2/df$), root mean square error of approximation (RMSEA), goodness-of-fit index (GFI), comparative fit index (CFI), and incremental fit index (IFI), was significant ($\chi^2/df = 1.78$; RMSEA = 0.08; RMSE = 0.085, 90% confidence interval (CI), 0.041-0.12; GFI = 0.92; CFI = 0.96; IFI = 0.96), and the convergent validity was significant with respect to mood ($P < 0.05$).

2.2.2 Screening of the Activity Limitation and Safety Awareness Scale

The SALSA scale was established by the SALSA Collaborative Study Group in 2007. The scale consists of 20 items and four subscales. The four subscales are mobility of foot, self-care, work of hand, and dexterity of hand. Twenty of the items have 5-point (0-4) Likert-type questions to evaluate the limitation of daily activity in limbs. Higher scores on the total scale represent more severe RDA. The reliability was significant for evaluating diabetic peripheral neuropathy (Kappa values ranged from 0.45 to 0.8). The reliability of the Chinese version of the SALSA scale for evaluating oxaliplatin-induced peripheral neuropathy was acceptable (the Cronbach's $\alpha$ coefficient of the total scale was 0.70), the content validity was good (item-level content validity indexes were 0.8-1.0; the average scale-level CVI was 0.89), and the criterion-related validity was significant with respect to mood ($P < 0.01$) and QoL ($P < 0.05$).

2.2.3 Profile of Mood States Short Form

POMS-SF was developed from the 65-item Profile of Mood States scale by Shacham in 1983. The scale is a self-administered questionnaire containing 30 items. The 30 items are a set of 5-point (0-4) adjective rating scales with a six-bipolar-factor structure. The six bipolar factors are tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment. Higher scores on the total scale indicate a more negative mood. The reliability of the Chinese version of POMS-SF was very high (Cronbach's $\alpha$ coefficients were 0.98-0.99), and the validity by factor analysis was significant ($P < 0.05$). The FACT-C version 4 was evaluated by Yoo and colleagues in 2005, which is a self-administered questionnaire. The instrument consists of 36 items and five domains. The five domains are physical well-being, social well-being, emotional well-being, functional well-being, and the colorectal cancer subscale. The 36 items have 5-point (0-4) Likert-type questions. Higher scores on the total scale indicate better QoL. The reliability (Cronbach's $\alpha$ coefficients were approximately 0.81-1.0) and concurrent validity of the Chinese version of the FACT-C version 4 significantly correlated with those of EORTC OLQ-C30/CR38 and SF-12 v2 ($r \geq 0.4$).

2.3 Data analysis

The data were analyzed using SPSS software (version 19.0; SPSS Inc, Chicago, IL). A descriptive basis (percentage distributions, means and standard deviations) was used to calculate the patients' characteristics and instrument scores. The bivariate correlations among CIPN, RDA, mood, and QoL were analyzed by Pearson's correlation coefficients. Hierarchical multiple linear regression analysis was used to measure the effects of CIPN, RDA and mood on QoL. When CIPN was set on covariates, medication effect analysis with multiple linear regressions was based on Baron and Kenney's method.

3 RESULTS

3.1 Patients' characteristics

The patients' characteristics are summarized in Table 1. Most of the patients were aged 61-70 years (34%), were male (55.3%), were married (79%), had a high school education level (45.6%), left work (63.1%), had stage III disease (60.2%), had hypertension (25.2%), had diabetes mellitus (15%), had spinal disease (5.8%), and had an accumulation dose of chemotherapy above 541 mg/m$^2$ (56.3%).

3.2 Scores of CIPN, RDA, mood, and QoL

The mean NSPI score was 13.66 (SD, 12.05; range, 1-68). Scores of the subscales on spontaneous neuropathic pain, paroxysmal neuropathic pain, evoked neuropathic pain, and dysesthesia/paresthesia were 1.95 (SD, 3.663), 2.17 (SD, 3.539), 4.90 (SD, 4.756), and 4.63 (43.25). Evoked neuropathic pain, especially that evoked by cold stimulation, and paresthesia (numbness/tingling) were the two major discomforts. The mean SALSA scale score was 19.50 (SD, 4.228; range, 11-33). Scores of the subscales on mobility of foot, self-care,
work of hand, and dexterity of hand were 3.44 (SD, 1.667), 3.29 (SD, 0.946), 6.83 (SD, 2.540), and 4.79 (SD, 1.348). The ranking of the SALSA subscales from high to low scores was self-care, dexterity of hand, mobility of foot, and self-care. The mean POMS-SF score was 28.92 (SD, 13.790; range 5-67). Of the 6 subscales of the POMS-SF, the vigor-activity subscale had the highest mean score. Scores of these subscales on tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment were 3.49 (SD, 3.534), 3.21 (SD, 2.996), 2.82 (SD, 2.882), 10.88 (SD, 4.453), 4.14 (SD, 3.106), and 4.39 (SD, 2.474).

The mean score on the FACT-C version 4 was 100.11 (SD, 15.877; range 60-134). The scores of subscales on physical well-being, social well-being, emotional well-being, functional well-being, and colorectal cancer subscale were 22.65 (SD, 4.08), 21.00 (SD, 4.548), 19.43 (SD, 3.706), 17.37 (SD, 5.792), and 19.66 (SD, 4.281). Among the 5 dimensions of the FACT-C version 4, the domain of physical well-being had the highest mean score.

### 3.3 Relationship among RDA, mood and QoL in colorectal patients with CIPN

The bivariate correlation between CIPN, RDA, mood, and QoL is listed in Table 2. There was a significantly positive relationship between paroxysmal neuropathic pain and self-care ($r = 0.249, P < 0.05$) as well as between dysesthesia/paresthesia and dexterity of hand ($r = 0.95, P < 0.05$). CIPN and negative mood showed a moderate significant positive correlation ($r = 0.425, P < 0.001$), but only a mild, significant negative correlation was observed between physical well-being and QoL ($r = -0.233, P < 0.05$). The RDA showed a intermediate positive correlation with mood ($r = 0.343, P < 0.01$).

Hierarchical multiple regression analysis was used to calculate the effect of CIPN, RDA and mood on QoL (Table 3). Model I showed a 2.2% variance of CIPN with no significant effect on QoL ($F = 2.2743, P > 0.05$). Model II showed a 9.6% variance of CIPN, and RDA showed a mild significant effect on QoL ($F = 5.316, P < 0.05$). Model III showed a 38.5% variance of CIPN, and RDA and mood showed a strong, significant effect on QoL ($F = 20.645, P < 0.001$).

The mediation model of RDA and mood on QoL showed in Table 3 that RDA was positively related to mood ($t = 3.6236, P < 0.01$), and mood had a significant negative association with QoL ($t = -6.8168, P < 0.001$). Under the inclusion of mood, the total effects of RDA had a significantly negative relationship with QoL ($t = -2.8628, P < 0.01$). There was no significant relationship between RDA and QoL when the mood (mediator) was the control ($t = -0.9239, P > 0.05$). CIPN was the control covariate, with no significant relationship with QoL ($t = 1.8950, P > 0.05$). In conclusion, the 38.48% variance of the model can explain the total mediation of mood on the effect of RDA on QoL in controlling CIPN (Figure 1). The mediation model of mood and RDA on QoL also showed in Table 3. Because model I was included in 95% CI, the mediation model was excluded.

### 4 DISCUSSION

The aim of this study was to investigate the relationships among RDA, mood, and QoL in colorectal cancer patients with CIPN. In this study, the patients’ characteristics of age and gender were similar to the global statistical data. A previous study revealed that CIPN regardless of concurrent...
RDA may induce a poorer mood or QoL. In this study, paroxysmal neuropathic pain and dysesthesia/paresthesia were associated with self-care and dexterity of hand, a finding that was also reported previously. For the first time, the present study revealed significant correlations of RDA with mood and QoL, compared with mild-to-moderate correlations of CIPN with mood and QoL. RDA likely had a stronger influence on mood and QoL than CIPN because only patients with mild-to-moderate CIPN were enrolled. Patients with severe CIPN should have been included in the study, but it was a challenging issue in clinical practice. Previous studies supported persistent severe CIPN may be irreversible, consequently inducing permanent RDA. Thus, patients with severe CIPN were omitted from oxaliplatin-based chemotherapy in clinical settings, and so would be excluded from the criteria of this study.

Additionally, most of the patients with mild-to-moderate CIPN had mild RDA. CIPN and RDA were associated with negative mood. Thus, spontaneous neuropathic pain, paroxysmal neuropathic pain, evoked neuropathic pain, and dysesthesia/paresthesia, as well as restrictions in foot mobility, self-care, work of hand, and dexterity of hand lead to many types of emotional distress, such as tension, anxiety, depression, dejection, anger, hostility, vigor, activity, fatigue, inertia, confusion, and bewilderment. Similar findings revealed that RDA in patients with CIPN may show annoyance, irritability, weariness, anger, frustration, and depression. Negative mood was found to possibly induce poorer QoL in this study. Similar findings of relationships between negative mood and QoL have been reported previously.

QoL is an endpoint of care for and treatment of cancer patients. According to the findings by hierarchical multiple linear regression analysis in this study, RDA, and negative mood can impact QoL more than CIPN. CIPN showed no significant effect on QoL. Thus, CIPN was set to be a covariate during mediation testing among RDA, mood, and QoL.

### TABLE 2 Correlation among CIPN, RDA, mood, and QoL

| NPSI | TS | SNP | PNP | ENP | DP |
|------|----|-----|-----|-----|----|
| SALSA scale | | | | | |
| TS | 0.095 | 0.049 | 0.013 | 0.093 | 0.111 |
| MF | 0.022 | 0.018 | −0.028 | −0.068 | 0.141 |
| SC | 0.130 | 0.013 | 0.249** | 0.054 | 0.098 |
| WH | −0.008 | 0.015 | −0.146 | 0.125 | −0.056 |
| DH | 0.151 | 0.085 | 0.106 | 0.064 | 0.195* |

| Mood | TS | SNP | PNP | ENP | DP |
|------|----|-----|-----|-----|----|
| TA | 0.372*** | 0.318** | 0.315** | 0.260*** | 0.234* |
| DD | 0.315** | 0.340 | 0.284** | 0.228** | 0.117 |
| AH | 0.334** | 0.319** | 0.360*** | 0.128 | 0.237* |
| VA | 0.315** | 0.250* | 0.167 | 0.247 | 0.261** |
| FI | 0.397*** | 0.384*** | 0.365* | 0.203* | 0.269** |
| CB | 0.303** | 0.197* | 0.333*** | 0.240* | 0.152 |

| FACT-C version 4 | TS | SNP | PNP | ENP | DP |
|------------------|----|-----|-----|-----|----|
| TS | −0.148 | −0.269* | −0.099 | −0.058 | −0.043 |
| PWB | −0.233* | −0.229 | −0.132 | −0.088 | −0.254* |
| SWB | −0.240 | −0.126 | 0.018 | −0.014 | 0.042 |
| EWB | −0.112 | −0.169 | −0.099 | −0.067 | −0.118 |
| FWB | −0.030 | −0.151 | 0.018 | 0.010 | 0.019 |
| CCS | −0.126 | −0.287 | −0.144 | −0.036 | 0.044 |

AH, anger-hostility; CB, confusion-bewilderment; CCS, colorectal cancer subscale; CIPN, chemotherapy-induced peripheral neuropathy; DD, depression-dejection; DH, dexterity of hand; DP, dysesthesiaparesthesia; ENP, evoked neuropathic pain; EWB, emotional well-being; FACT-C, Functional Assessment Cancer Therapy-Colorectal scale; FI, fatigue-inertia; MF, mobility of foot; NPSI, Neuropathic Pain Symptoms Inventory; PNP, paroxysmal neuropathic pain; PWB, physical well-being; QoL, quality of life; RDA, restriction of daily activity; SALSA, Screening of Activity Limitation and Safety Awareness; SC, self-care; SNP, spontaneous neuropathic pain; SWB, social well-being; TA, tension-anxiety; TS, total score; VA, vigor-activity; WH, work of hand.

*P < 0.05
**P < 0.01
***P < 0.001
Furthermore, negative mood can totally influence the effect of RDA on QoL. The two viewpoints are new findings in this study. Tracing the possible reason, the population in this study had a lower severity of CIPN and RDA, which may lead to fewer effects on QoL. Negative mood also commonly occurred in colorectal cancer patients. Although mood may overlap with the emotional well-being of QoL, the overlaps were not conflicting. Under the operational definition of concept in instruments, POMS-SF measured the negative mood by the frequency of the patients' adjective concept, and FACT-C version 4 evaluated the QoL by the frequency of events. When measuring the operational definition of a concept, each sub-concept should not be divided. Based on the same reason, NPSI evaluated the severity of pain by numerical measure and SALSA scale measured bivariate events, which were also different from the one of FACT-C version 4.

### Table 3: Relationships between CIPN, RAD, mood, and QoL

| Model          | Variables       | $R^2$ | Lower   | Upper   | $F$  | $\beta$ | SE   | $t$  |
|----------------|-----------------|-------|---------|---------|------|---------|------|------|
| Model I        |                 | 0.022 | 98.102  | 107.468 | 2.274 | 102.785 | 2.361 |      |
| CIPN           |                 |       |         |         |      | -0.196  | 0.130 | -1.508|
| Model II       | CIPN            | 0.096*| 108.049 | 136.611 | 5.316*| 122.330 | 2.361 |      |
| RDA            |                 |       |         |         |      | -0.162  | 0.126 | -1.281|
| Model III      | CIPN            | 0.385***| 112.542 | 136.257 | 20.645***| 124.400 | 5.976 |      |
| RDA            |                 |       |         |         |      | -0.2922 | 0.316 | -0.924|
| Mood           |                 |       |         |         |      | -0.750  | 0.110 | -6.817***|

Mediation effects between RDA and Mood on QoL

| RDA (predictor) → Mood (mediator) | 0.3848 | -1.3375 | -0.2254 | 20.649*** |
| RDA (predictor) → QoL (outcome)   | 0.9799 | 0.2704  | 3.6236** |
| Mood (mediator) → QoL (outcome)   | -0.7496| 0.1100  | -6.8168* |
| RDA (predictor) → QoL (outcome)   | -1.0267| 0.3586  | -2.8628**|
| RDA (predictor) → QoL (outcome)   | -0.2922| 0.3163  | -0.9239 |

Control covariance (CIPN)

| 0.2256 | 0.1191 | 1.8950 |

RDA mediates the effect of Mood on QoL

| Mood (predictor) → RDA (mediator) | 0.1241 | 0.0353 | -0.0981 | 7.0826 |
| RDA (mediator) → QoL (outcome)    | 0.1184 | 0.0327 | 3.6236***|
| Mood (predictor) → QoL (outcome)  | -0.2922| 0.3163 | -0.9239 |
| Mood (predictor) → QoL (outcome)  | -0.7496| 0.1100 | -6.8168* |
| Mood (predictor) → QoL (outcome)  | 16.5009| 0.9206 | 17.9234***|

Control covariance (CIPN)

| -0.0316 | 0.0375 | 0.4018 |

CIPN, chemotherapy-induced peripheral neuropathy; QoL, quality of life; RDA, restriction of daily activity.

$^* P < 0.05$

$^{**} P < 0.01$

$^{***} P < 0.001$
By the mediation effect analysis, a new finding was noted in the study. Mood was a total mediator of RDA in QoL with the covariate CIPN. Thus, managing CIPN and RDA may not significantly improve QoL in colorectal cancer patients. Until their emotional problems are resolved, patients may continue to experience reduced QoL. This finding could explain why physicians were less concerned with the influence of CIPN in clinical practice.10,11 It is also possible that there was no actual influence of mild-to-moderate CIPN or mild RDA on QoL. Based on our findings, seriously evaluating patients’ emotional status is necessary when caring for colorectal cancer patients with CIPN and RDA. Another one innovative viewpoint should be discussed, which is the possibility of a pathway from CIPN induced RDA, and then mood on QoL. In the fact, the pathway ever be analyzed by this study researchers, but its results excluded the routine. The cause was supposed to be a limitation in the population with mild-to-moderate CIPN. Another probability of limitation was methods of evaluating peripheral neuropathy. The methods of nerve conduction studies and quantitative sensory testing were not used in this study because there was no proper evaluation tool.31

Overall, the results of this study indicated that RDA in colorectal cancer patients with CIPN can induce a negative mood, which can then interfere with QoL. To avoid irreversible symptoms and maintain the treatment principle of do-no-harm, care specialists should conduct comprehensive evaluation and effective management of CIPN and RDA. The findings in this study strongly caution that care specialists must also actively evaluate and support patients’ emotional status, which may strongly promote QoL. Nevertheless, preventing irreversible CIPN, avoiding permanent RDA and maintaining mental hygiene are recommended to care specialists for the purpose of promoting QoL in colorectal cancer patients with CIPN. Finally, there were strong suggestions in clinical practice to evaluate patients’ mood status in daily routine and set up a criteria for consultation of social workers, psychologists, and psychiatrists.

5 | LIMITATIONS

Participation was limited to colorectal patients with mild-to-moderate oxaliplatin-induced peripheral neuropathy at two hospitals in Taiwan. The study had a cross-sectional design that did not allow generalized findings throughout the longitudinal treatment course. In addition, multiple linear regression analysis could predict a trend between variables but could not prove the real cause effect between variables.

6 | CONCLUSION

Based on the findings in this study, CIPN is a confounder of the relationships among RDA, mood, and QoL in colorectal cancer patients. Although the correlations between CIPN, mood, RDA, and QoL were around mild to moderate, all of them were significant. Mood is the strongest factor impacting QoL, especially in patients with mild-to-moderate CIPN and mild RDA. Managing and helping patients with CIPN and RDA as well as adjust their negative mood are very important in promoting QoL in colorectal cancer patients receiving oxaliplatin-based chemotherapy.

ACKNOWLEDGMENT
We sincerely thank the friendly support from colleagues at the Hematology & Oncology Department, Koo-Found, Sun Yat-Sen Cancer Center and Taipei Tzu Chi Hospital.

CONFLICTS OF INTEREST
The corresponding authors are employed by educational institutes, and the first author and coauthors are employed by the hospital. They are educators and primary care specialists with no conflicts of interest.

ORCID
Chieh-Yu Liu https://orcid.org/0000-0003-3283-028X

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386. https://doi.org/10.1002/ijc.29210
2. NCCN.org [homepage on the internet]. NCCN Clinical Guidelines in Oncology: Colon Cancer & Rectal Cancer. NCCN.org/http://www.nccn.org/. Accessed March 13, 2017.

3. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol. 2006;56(1):13-16. https://doi.org/10.1159/000094376.

4. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438-444. https://doi.org/10.1002/cncr.27732.

5. Dault R, Rousseau MP, Beaudoin A, Frenette MA, Lemay F, Davis EE. Oxaliplatin-induced peripheral neuropathy: a university of Rochester CCOP experience. J Oncol Nurs. 2016;23(1):e65-e69. https://doi.org/10.3747/jcon.20.23.2780.

6. Gupta R, Bhaskar A. Chemotherapy-induced peripheral neuropathic pain. BJA Educ. 2016;16(4):115-119. https://doi.org/10.1093/bjaed/mkv044.

7. Lu LC, Chang SY, Liu CY, Tsay SL. Reliability and validity of the Chinese version Neuropathic Pain Symptom Inventory in patients with colorectal cancer. J Formos Med Assoc. 2018;117:1091-1026. https://doi.org/10.1016/j.jfma.2017.11.010.

8. Kanda K, Fujimoto K, Kyota A. Emotional responses to persistent chemotherapy-induced peripheral neuropathy experienced by patients with colorectal cancer in Japan. Asia Pac J Oncol Nurs. 2017;4(3):233-240. https://doi.org/10.4103/apjon.apjon_12_17.

9. Toftthagen C, Visovsky CM, Hopgood R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin J Oncol Nurs. 2013;17(2):138-144. https://doi.org/10.1188/13.CJON.138-144.

10. Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007;56(5):323-331. https://doi.org/10.1097/01.NNR.0000289503.22414.79.

11. Tanay M, Armes J, Ream E. The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care. 2017;26(5):1-13. https://doi.org/10.1111/ecc.12443.

12. Gewandter JS, Fan L, Magnuson A, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a university of Rochester CCOP study. Support Care Cancer. 2013;21(7):2059-2066. https://doi.org/10.1007/s00520-013-1766-y.

13. Driessen C, de Kleine-Bolt K, Vingerhoets A, Mols F, Vreugdenhil G. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer. 2012;20(4):877-881. https://doi.org/10.1007/s00520-011-1336-0.

14. Toftthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21(12):3307-3313. https://doi.org/10.1007/s00520-013-1905-5.

15. Mystakidou K, Tsilika E, Parpa E, Pathiaki M, Galanos A, Vlahos L. The relationship between quality of life and levels of hopelessness and depression in palliative care. Depress Anxiety. 2008;25(9):730-736. https://doi.org/10.1002/da.20319.

16. Ye ZJ, Qiu HZ, Li PF, et al. Predicting changes in quality of life and emotional distress in Chinese patients with lung, gastric, and colon-rectal cancer diagnoses: the role of psychological resilience. Psychooncology. 2017;26(6):829-835. https://doi.org/10.1002/pon.4237.

17. Utne I, Miaskowski C, Bjordal K, Paul SM, Rustoen T. The relationships between mood disturbances and pain, hope, and quality of life in hospitalized cancer patients with pain on regularly scheduled opioid analgesic. J Palliat Med. 2010;13(3):311-318. https://doi.org/10.1089/jpm.2009.0294.

18. Bouhassira D, Attal N, Fermandjian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108(3):248-257. https://doi.org/10.1016/j.pain.2003.12.024.

19. Crawford B, Bouhassira D, Wong A, Dukes E. Conceptual adequacy of the Neuropathic Pain Symptom Inventory in six countries. Health Qual Life Outcomes. 2008;6:62. https://doi.org/10.1186/1477-7525-6-62.

20. The Salsa Collaborative Study Group. The development of a short questionnaire for screening of activity limitation and safety awareness (SALSA) in clients affected by leprosy or diabetes. Disabil Rehabil. 2007;29(9):689-700. https://doi.org/10.1080/09638280600926587.

21. Ebenso J, Velema JP. Test-retest reliability of the screening activity limitation and safety awareness (SALSA) scale in north-west Nigeria. Lepr Rev. 2009;80(2):197-204.

22. Ping-Chun L. The reliability and validity of Screening of Activity Limitation and Safety Awareness (SALSA) Scale Chinese version in colorectal cancer patients with chemotherapy-induced neuropathy. http://conferenceseries.com/. Accessed September 13, 2017.

23. Shacham S. A shortened version of the profile of mood states. J Pers Assess. 1983;47(3):305-306. https://doi.org/10.1207/s15327752jpa4703_14.

24. Chen KM, Snyder M, Krichbaum K. Translation and equivalence: the profile of mood states short form in English and Chinese. Int J Nurs Stud. 2002;39(6):619-624. https://doi.org/10.1016/S0020-7489(01)00068-2.

25. Chen KM, Snyder M, Krichbaum K. Tai Chi and well-being of Taiwanese community-dwelling elders. Clin Gerontol. 2001;24:137-156.

26. Yoo HJ, Kim JC, Eremenco S, Han OS. Quality of life in colorectal cancer patients with colectomy and the validation of the functional assessment of cancer therapy-colorectal (FACT-C), version 4. J Pain Symptom Manage. 2005;30(1):24-32. https://doi.org/10.1016/j.jpainsymman.2004.12.009.

27. Wong C, Lam C, Law WL, et al. Validity and reliability study on traditional Chinese FACT-C in Chinese patients with colorectal neoplasm. J Eval Clin Pract. 2012;18(6):1186-1195. https://doi.org/10.1111/j.1365-2753.2011.01753.x.

28. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173-1182. https://doi.org/10.1037/0022-3514.51.6.1173.

29. Krase MR, Serlin RC, Ward SE, Rony RY, Ezenwa MO, Naab F. Testing mediation in nursing research: beyond Baron and Kenny. Nurs Res. 2010;59(4):288-294. https://doi.org/10.1097/NNR.0b013e3181dd26b3.
30. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. *Oncologist*. 2011;16(5):708-716. https://doi.org/10.1634/theoncologist.2010-0248

31. Smith E, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. *Oncol Nurs Forum*. 2008;35(1):96-102. https://doi.org/10.1188/08.ONF.96-102

How to cite this article: Lu L-C, Tsay S-L, Chang S-Y, Chen C-M, Liu C-Y. Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: A mediation effect analysis. *Cancer Med*. 2019;8:963–971. https://doi.org/10.1002/cam4.1976